CCM
FOLD

Cadence Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Cadence Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-65,150
Closed -$542K – 624
2014
Q4 		$542K Buy
+65,150
New +$447K 0.03% 490

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cadence Capital Management's FOLD Position: Q1 2015 in Review

Cadence Capital Management sold out of Amicus Therapeutics (FOLD) in Q1 2015, closing a stake of 65,150 shares — an estimated $542K sold.

Cadence Capital Management first reported a position in FOLD in Q4 2014 and held it in 1 quarter. The position peaked at $542K in Q4 2014. 125 funds tracked by Wall St. Rank hold FOLD as of Q1 2015.

  • Cadence Capital Management reported no remaining Amicus Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Cadence Capital Management sold 65,150 Amicus Therapeutics shares in Q1 2015, an estimated $542K.
  • Cadence Capital Management first reported a position in Amicus Therapeutics in Q4 2014 and held it in 1 quarter.
  • Cadence Capital Management's Amicus Therapeutics position peaked at $542K in Q4 2014.
  • 125 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2015.

Based on Cadence Capital Management's 13F filing for Q1 2015, filed 30 Apr 2015.